Tenet Shakes Things Up
Executive Summary
Just a few years ago, Tenet was overshadowed nearly to invisibility by the Columbia/HCA juggernaut. Now it has reversed roles, and suppliers have come courting. But instead of playing by traditional group purchasing rules, Tenet hopes to make its mark by going in the opposite direction from everyone else, shaking up a stagnant industry.
You may also be interested in...
Xtandi Still Faces Likely US Price Cut Even As It Avoids ‘March In’ Proceeding
The Biden administration decision not to pursue ‘march in’ proceedings for Pfizer/Astellas’ Xtandi sounds like good news. The reality is that the prostate cancer therapy is likely to face a more certain federal pricing intervention in the first year of the new Medicare ‘negotiation’ process.
Moderna CEO Reminds People About Value Of Government Negotiations At Senate Hearing
Stéphane Bancel also gave conflicting answers for how the company set the cost of its mRNA COVID-19 vaccine as Democratic lawmakers tried to berate Moderna for its coming price hikes. Republicans lawmakers argue against retroactive shaming, saying that if the government wanted to set the eventual commercial price, it should have done that early in negotiations.
Accelerated Approval: Potential Sources Of Confirmatory Evidence Weighed At Tofersen Review
‘Clear signal’ in the ATLAS study of presymptomatic, SOD1 mutation carriers could provide evidence needed to confirm tofersen’s benefit in symptomatic ALS patients, FDA’s Teresa Buracchio says, adding that getting confirmatory evidence from the VALOR open-label extension 'could be a little more tricky.'